Legal Representation
Attorney
Brian E. Turung
USPTO Deadlines 2 active 2 overdue
Deadline Type | Event Code | Deadline Date | Days Until | Priority | Extension Available |
---|---|---|---|---|---|
OPPOSITION
Notice of Publication |
NPUB | Jan 24, 2019 | 2356 days overdue | Medium | Until Feb 24, 2019 |
ITU SOU
Notice of Allowance Mailed - SOU Required |
NOAM | Aug 19, 2019 | 2149 days overdue | High | Until Feb 19, 2020 |
Application History
50 eventsDate | Code | Type | Description |
---|---|---|---|
Feb 15, 2023 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
Apr 19, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
Mar 15, 2022 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
Mar 13, 2022 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
Mar 1, 2022 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
Feb 18, 2022 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
Feb 18, 2022 | IUAF | S | USE AMENDMENT FILED |
Aug 10, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Aug 9, 2021 | EX5G | S | SOU EXTENSION 5 GRANTED |
Aug 6, 2021 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Jul 28, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Jul 28, 2021 | EXT5 | S | SOU EXTENSION 5 FILED |
Feb 17, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Feb 15, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Feb 15, 2021 | EXT4 | S | SOU EXTENSION 4 FILED |
Feb 15, 2021 | EX4G | S | SOU EXTENSION 4 GRANTED |
Oct 5, 2020 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
Oct 5, 2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Oct 5, 2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Oct 5, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Oct 5, 2020 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
Aug 21, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Aug 19, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Aug 19, 2020 | EXT3 | S | SOU EXTENSION 3 FILED |
Aug 19, 2020 | EX3G | S | SOU EXTENSION 3 GRANTED |
Feb 28, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Feb 27, 2020 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Feb 27, 2020 | EX2G | S | SOU EXTENSION 2 GRANTED |
Feb 18, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Feb 18, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Feb 18, 2020 | EXT2 | S | SOU EXTENSION 2 FILED |
Aug 20, 2019 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Aug 16, 2019 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Aug 16, 2019 | EXT1 | S | SOU EXTENSION 1 FILED |
Aug 16, 2019 | EX1G | S | SOU EXTENSION 1 GRANTED |
Feb 19, 2019 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Jan 30, 2019 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
Dec 25, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION |
Dec 25, 2018 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Dec 5, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Nov 12, 2018 | ALIE | A | ASSIGNED TO LIE |
Oct 28, 2018 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
Oct 26, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Oct 26, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Oct 26, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Apr 30, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN |
Apr 30, 2018 | GNRT | F | NON-FINAL ACTION E-MAILED |
Apr 30, 2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Apr 26, 2018 | DOCK | D | ASSIGNED TO EXAMINER |
Jan 29, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Detailed Classifications
Class 001
Food products containing probiotic compositions, namely, probiotic bacteria and probiotic bacterial cultures for use as a food additive for food manufacturing; human food products containing probiotic compositions, namely, probiotic bacteria and probiotic bacterial cultures for use as a food additive for food manufacturing; animal food products containing probiotic compositions, namely, nutritional additives for use in manufacturing animal feed
First Use Anywhere:
Feb 17, 2022
First Use in Commerce:
Feb 17, 2022
Class 005
Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for medical use for improving the physical well-being of humans, namely, reducing inflammation and pain; dietary supplements for medical use, and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal and bacterial probiotic supplements, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome; beverages containing probiotic compositions for use as a nutritional supplement; food supplements containing probiotic compositions; human food supplements products containing probiotic compositions; animal food products containing probiotic compositions, namely, probiotic animal feed; dietary supplement drink mixes, namely, probiotic compositions in the form of mixes to added to beverages; dietary supplements in the nature of probiotic compositions for mixing with cereal
First Use Anywhere:
Feb 17, 2022
First Use in Commerce:
Feb 17, 2022
Classification
International Classes
001
005